Lucid Diagnostics Q3 revenue misses analyst expectations
LUCD•Lucid Diagnostics reported Q3 revenue of $1.20 million, below the $1.64 million analyst consensus, while adjusted loss per share of $0.06 met expectations. The company said nationwide Medicare reimbursement for EsoGuard and record monthly test volume in October support expected revenue growth acceleration.
1. Quarterly results
Lucid Diagnostics reported Q3 revenue of $1.20 million, compared with analyst expectations of $1.64 million. Adjusted loss per share was $0.06, matching the consensus estimate.
2. Medicare coverage and outlook
The company said nationwide Medicare reimbursement for EsoGuard marks a shift toward commercial acceleration and revenue growth. It reported record monthly EsoGuard test volume in October following Medicare payments and said it is expanding coverage through additional health plans and VA programs. Lucid said near-term growth depends on commercial and operational execution.
